Minute Insight: Theranica’s Wearable Earns Expanded FDA Clearance For Preventing Migraines
Executive Summary
Theranica’s expanded US FDA clearance allows the company to market its prescription-based wearable as both an acute and preventive treatment for migraine headaches.
You may also be interested in...
‘Training People To Be Healthier’: Digital Therapeutics Programmed For Growth
Experts foresee the digital therapeutics market growing to $6bn-$9bn by 2025, driven in part by tech-empowered consumers and patients looking for solutions to better manage their own health and conditions. For medtechs, collaborations with software-driven start-ups will be key to harnessing personalized data and differentiating themselves in the marketplace.
US Medicare Creates New Code For Theranica’s Headache Device
Medicare beneficiaries suffering from migraines will soon have access to an innovate drug-free treatment at the touch of their smartphones.
Newer Therapy Areas Will Drive Women’s Health Funding In 2024
Women’s health startups focusing on areas of high unmet need such as menopause, infertility, preventive care and post-partum care will continue to attract investors in 2024. Meanwhile, machine learning and AI, as well as next-generation treatments such as psychedelic therapy, stand to drive advancements in the space.